Search Results

GW5074 50mg  | 99.54%

APEXBIO TECHNOLOGY LLC

C-Raf inhibitor,potent and selective MAPK Signaling|Raf

More Information Supplier Page

×

GW5074

GW5074 5mg  | 99.54%

APEXBIO TECHNOLOGY LLC

C-Raf inhibitor,potent and selective MAPK Signaling|Raf

More Information Supplier Page

×

GW5074

GW5074 10mM (in 1mL DMSO)  | 99.54%

APEXBIO TECHNOLOGY LLC

C-Raf inhibitor,potent and selective MAPK Signaling|Raf

More Information Supplier Page

×

GW5074

DCC-2036 (Rebastinib) 50mg  | 98%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor TGF-β / Smad Signaling|Bcr-Abl

More Information Supplier Page

×

DCC-2036 (Rebastinib)

GZD824 5mg  | 99.83%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor,novel orally bioavailable Tyrosine Kinase|Bcr-Abl

More Information Supplier Page

×

GZD824

GZD824 25mg  | 99.83%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor,novel orally bioavailable Tyrosine Kinase|Bcr-Abl

More Information Supplier Page

×

GZD824

DCC-2036 (Rebastinib) 10mM (in 1mL DMSO)  | 98%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor TGF-β / Smad Signaling|Bcr-Abl

More Information Supplier Page

×

DCC-2036 (Rebastinib)

DCC-2036 (Rebastinib) 5mg  | 98%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor TGF-β / Smad Signaling|Bcr-Abl

More Information Supplier Page

×

DCC-2036 (Rebastinib)

DCC-2036 (Rebastinib) 10mg  | 98%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor TGF-β / Smad Signaling|Bcr-Abl

More Information Supplier Page

×

DCC-2036 (Rebastinib)

GZD824 10mM (in 1mL DMSO)  | 99.83%

APEXBIO TECHNOLOGY LLC

Bcr-Abl inhibitor,novel orally bioavailable Tyrosine Kinase|Bcr-Abl

More Information Supplier Page

×

GZD824